CJC-1295 (without DAC) vs Letrozole
Well Studied vs FDA Approved
synergistic Mechanism-based · 60% Letrozole helps manage estrogen conversion from CJC-1295 (without DAC). This is a common and recommended combination. Adjust AI dose based on bloodwork — avoid crashing estrogen.
Molecular Data
CJC-1295 (without DAC) Letrozole
Weight 3,367.97 Da 285.30 Da
Half-life 30 minutes - 2 hours ~2 days (48 hours)
Chain 30 amino acids —
Type GHRH analog Nonsteroidal aromatase inhibitor (triazole derivative)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Letrozole
01 Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
02 Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
03 Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
04 Oral dosing with a 2-day half-life supports every-other-day scheduling
05 Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
06 Reversible inhibition allows estrogen recovery after discontinuation
07 FDA-approved with decades of safety and efficacy data
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Letrozole
0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical) / Every other day (cycle support); daily (breast cancer / fertility)
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Letrozole
Severe joint pain, stiffness, and dryness (the hallmark side effect of aggressive estrogen suppression)
Fatigue and profound lethargy
Mood disturbance (depression, emotional flatness, irritability)
Decreased libido and sexual dysfunction
Hot flashes or flushing
Headache
Muscle aches and generalized pain
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Known hypersensitivity to letrozole or any excipients
Premenopausal women (unless under specialist care for fertility treatment)
Pregnancy or breastfeeding (teratogenic risk -- letrozole is Category X)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
History of estrogen-crash-related adverse events with prior AI use
Research Evidence
CJC-1295 (without DAC) Letrozole
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest November 2024 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.